If you want to prepare yourself for the next 10 years of your career, then I invite you to join me at this year's 2018 ISPE Biopharmaceutical Manufacturing Conference, 10 -12 December, Huntington Beach, California, a conference focused on a fascinating and challenging future that is just around the corner. Our theme says it all…..
We’ve brought together regulators and practitioners who are meeting the challenge of industrializing personalized medicine, expanding into Oligonucleotides and ADC’s, and charting the path to Continuous Biomanufacturing. Register now to learn and network with these industry and regulatory leaders who are on the forefront of this transformation.
As novel therapies emerge from the clinic and provide dramatic improvement in disease treatment, the biopharmaceutical professional of today must be prepared to design, build, operate, and support the new and different facilities and processes required to meet demand. To twist a phrase, “This won’t be your parents biopharm plant”
If you’ve started on this journey, then come share and compare experiences with our talented speaker panels during Q&A and networking sessions, take new information away, and help your peers learn from your experiences.
Highlights include:
I hope you will join me in California this December as we explore, strategize, develop tools, and determine how to navigate the evolving technical and regulatory complexities of biopharm’s exciting future. Register now to learn and network with industry, academic researchers and regulatory leaders who are on the forefront of this transformation.
Best regards,
In the pharmaceutical industry, which is highly regulated, aseptic processing is a critical component that ensures the sterility of products. Regulators have a set of comprehensive requirements that minimize the risk of contamination. Regulators set the requirements; however, the industry has an obligation to the patients who rely on and expect a drug that is safe and free of contamination....
Like any investment in digital manufacturing systems, demonstrating business payback before and after investment is critical to getting MES projects approved and verifying profitability after investment. Whether it is introducing MES, expanding it to additional sites, switching software, upgrading existing software, or developing electronic production records (EPR) for new drug products,...
Sustainability is emerging as a pivotal force influencing the pharmaceutical industry’s dynamics and steering companies towards transformative change. The focus of this analysis is to delve into the sustainability key performance indicators (KPIs) of prominent pharmaceutical players, namely Pfizer, Sanofi, Glaxo Smith Kline (GSK), Becton Dickinson, Johnson & Johnson, Abbott, Eli Lilly, and...